Recent health policy efforts have attempted to promote constructive conversations regarding cost-effectiveness by increasing transparency for both patients and physicians. Spurred by access and cost challenges resulting from increasing pharmaceutical prices, the Centers for Medicare & Medicaid Services (CMS) proposed a rule that would require direct-to-consumer prescription drug advertisements to include the list price for a typical 30-day course of therapy, according to their weighted average cost.1 Even though there may be debates about the right price, this critical step forward is built on the foundation of previously implemented regulations requiring hospitals to publicly post their hospital charge description master or chargemasters.2 This Viewpoint discusses implementing price transparency for health care products and services where physicians spend an increasing proportion of their time—in electronic health records (EHRs).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Miller BJ, Slota JM, Ehrenfeld JM. Redefining the Physician’s Role in Cost-Conscious Care: The Potential Role of the Electronic Health Record. JAMA. 2019;322(8):721–722. doi:https://doi.org/10.1001/jama.2019.9114
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: